是时候改变2型糖尿病治疗范式了吗?是的!GLP-1受体激动剂应取代二甲双胍在2型糖尿病治疗流程中的地位
本文为观点-反观点辩论。Abdu-Ghani与DeFronzo提出,2型糖尿病治疗应基于纠正高血糖背后的病理生理异常,因此一线治疗应从二甲双胍改为GLP-1受体激动剂;Inzucchi则主张基于医学界广泛经验及药物疗效、安全性、低成本和心血管获益,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的「基础治疗」。
要点
- 多数指南(包括ADA/EASD和国际糖尿病联盟)建议在饮食和运动后使用二甲双胍作为一线治疗。
- Abdu-Ghani与DeFronzo认为,针对血糖但未纠正潜在病理 disturbance 的干预不太可能对疾病过程产生持续获益。
- Inzucchi认为,基于医学界广泛经验及药物疗效、安全性、低成本和心血管获益,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的「基础治疗」。
核心结论
- Abdu-Ghani与DeFronzo认为,基于纠正高血糖潜在病理生理异常的治疗策略是最佳治疗策略,这要求将一线治疗推荐从二甲双胍改为GLP-1受体激动剂。
- Inzucchi认为,基于医学界广泛经验及药物疗效、安全性、低成本和心血管获益,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的「基础治疗」。
研究设计与样本
- 本文为观点-反观点辩论,由Abdu-Ghani与DeFronzo撰写正方观点,Inzucchi撰写反方观点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most treatment guidelines, including those from the American Diabetes Association/European Association for the Study of Diabetes and the International Diabetes Federation, suggest metformin be used as the first-line therapy after diet and exercise. This recommendation is based on the considerable body of evidence that has accumulated over the last 30 years, but it is also supported on clinical grounds based on metformin's affordability and tolerability. As such, metformin is the most commonly used oral antihyperglycemic agent in the U.S. However, based on the release of newer agents over the recent past, some have suggested that the modern approach to disease management should be based upon identification of its etiology and correcting the underlying biological disturbances. That is, we should use interventions that normalize or at least ameliorate the recognized derangements in physiology that drive the clinical manifestation of disease, in this circumstance, hyperglycemia. Thus, it is argued that therapeutic interventions that target glycemia but do not correct the underlying pathogenic disturbances are unlikely to result in a sustained benefit on the disease process. In our field, there is an evolving debate regarding the suggested first step in diabetes management and a call for a new paradigm. Given the current controversy, we provide a Point-Counterpoint debate on this issue. In the point narrative below that precedes the counterpoint narrative, Drs. Abdul-Ghani and DeFronzo provide their argument that a treatment approach for type 2 diabetes based upon correcting the underlying pathophysiological abnormalities responsible for the development of hyperglycemia provides the best therapeutic strategy. Such an approach requires a change in the recommendation for first-line therapy from metformin to a GLP-1 receptor agonist. In the counterpoint narrative that follows Drs. Abdul-Ghani and DeFronzo's contribution, Dr. Inzucchi argues that, based on the medical community's extensive experience and the drug's demonstrated efficacy, safety, low cost, and cardiovascular benefits, metformin should remain the "foundation therapy" for all patients with type 2 diabetes, barring contraindications.-William T. CefaluChief Scientific, Medical & Mission Officer, American Diabetes Association.
引用
- Abdul-Ghani M, DeFronzo RA. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care. 2017. PMID: 28733377. doi:10.2337/dc16-2368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。